Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ179MR)

This product GTTS-WQ179MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Cancers, non-small cell lung (NSCLC), Coat's disease research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ179MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6783MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DS-8201
GTTS-WQ258MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 17-1A
GTTS-WQ6883MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA E-6011
GTTS-WQ12626MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ10300MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LGT209
GTTS-WQ4640MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-986016
GTTS-WQ8576MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ4501MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-936557
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW